There are currently 953 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Reduced-dose Botox for Urgency Incontinence Among Elder Females
NCT05512039
Recruiting
The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
Gender:
FEMALE
Ages:
70 years and above
Trial Updated:
02/06/2025
Locations: University of Alabama - Birmingham, Birmingham, Alabama
Conditions: Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
Register for Updates
Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus
NCT06232304
Recruiting
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
02/05/2025
Locations: University of Alabama Birmingham Hospital, Birmingham, Alabama
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder)
Register for Updates
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
NCT04835129
Recruiting
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
Register for Updates
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
NCT05204888
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: UAB School of Medicine/Lung Health Center, Birmingham, Alabama
Conditions: COPD
Register for Updates
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
NCT06420531
Recruiting
The goal of this multi-center randomized, parallel group trial is to determine the effect of human milk diets ranging between 180 and 200 mL/kg/day on the body composition outcomes of moderately preterm infants born between 27 and 31 weeks of gestation.
Gender:
ALL
Ages:
Between 6 hours and 4 days
Trial Updated:
02/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Prematurity
Register for Updates
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
NCT06229353
Recruiting
To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
02/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Human Papilloma Virus
Register for Updates
Hybrid Type I Effectiveness-Implementation Trial of Project nGage
NCT05723653
Recruiting
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project nGage, an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black men and women ages 18-49.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/04/2025
Locations: University of Alabama at Birmingham 1917 Clinic, Birmingham, Alabama +1 locations
Conditions: HIV Seropositivity
Register for Updates
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
NCT04131413
Recruiting
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
02/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: UAB Division of Hematology/Oncology, Birmingham, Alabama
Conditions: Myelofibrosis
Register for Updates
STROKE STAT (Stroke Severity-based Triage to Accelerate Treatment)
NCT04978480
Recruiting
Acute stroke systems of care should emulate trauma systems which deliver the full range of care to all injured patients by means of organized, coordinated efforts in defined geographic areas. Just as trauma systems have proven ability to save lives of the most severely injured patients, clinicians should have a stroke system able to provide care to patients with the most severe strokes. The most severe type of acute ischemic stroke is due to proximal large vessel occlusion (LVO). Mechanical thro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Stroke
Register for Updates
Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy
NCT06309693
Recruiting
In the effort to reduce postoperative opioid use, there has been increasing interest in developing multimodal pain regimens to better manage postoperative pain while minimizing opioid use and their subsequent side effects that can be detrimental to the healing process. Standard of care approaches to better manage postoperative pain include the Enhanced Recovery After Surgery (ERAS) protocol and the use of peripheral and truncal nerve blocks. Truncal nerve blocks are widely used as an additional... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pelvic Organ Prolapse, Post Operative Pain
Register for Updates
Nasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis
NCT02038166
Recruiting
The purpose of this study is to determine if acquired (partial) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized environment that impairs mucociliary clearance (MCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Rhinosinusitis
Register for Updates